Award Number: W81XWH-13-1-0412

TITLE: Seminal Plasma Proteins as Androgen Receptor Corregulators Promote Prostate Cancer Growth

PRINCIPAL INVESTIGATOR: Hiroshi Miyamoto

CONTRACTING ORGANIZATION: Johns Hopkins University
                                                  Baltimore, MD 21218

REPORT DATE: December 2016

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
                         Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                                         Distribution Unlimited

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
December 2016	Final	23 Sep 2013 - 22 Sep 2016

4. TITLE AND SUBTITLE

Seminal Plasma Proteins as Androgen Receptor Corregulators Promote Prostate Cancer Growth

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-13-1-0412

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
Hiroshi Miyamoto

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

E-Mail: hiroshi_miyamoto@urmc.rochester.edu

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Johns Hopkins University
600 N. Wolfe Street, Baltimore,
Maryland 21287

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

We hypothesized that semenogelins, especially semenogelin I (SgI) in the presence of zinc, promote prostate cancer growth via functioning as androgen receptor (AR) co-activators. Using cell lines stably expressing SgI, we investigated biological functions of SgI in prostate cancer. Zinc, without SgI, inhibited cell growth of both AR-positive and AR-negative lines. Co-expression of SgI prevented zinc inhibiting androgen-mediated proliferation of AR-positive cells, whereas SgI and/or androgen showed marginal effects in AR-negative cells. Culture in the conditioned medium containing secreted forms of SgI failed to significantly increase cell viability with or without zinc. Similar effects of SgI overexpression on androgen-induced cell invasion, such as its significant enhancement with zinc, were seen. Overexpression of SgI also augmented androgen-mediated prostate-specific antigen (mRNA, protein) in the presence of zinc. In luciferase assays, SgI showed even slight inhibitory effects at 0 μM zinc and significant stimulatory effects at 100 μM zinc on androgen-enhanced AR transactivation. Using co-immunoprecipitation, we demonstrated androgen-induced physical interactions between AR and SgI. These results suggest that intracellular SgI, together with zinc, functions as an AR co-activator and thereby promotes androgen-mediated prostate cancer progression. We further found that SgI did not interact with other steroid hormone receptors, including estrogen receptors and glucocorticoid receptor, and did not significantly affect AR N/C-terminus interactions. More importantly, the LxxLL motif (L=leucine; x=any amino acids) present in SgI is likely to be essential and sufficient for mediating the interaction with AR. We further showed in vitro data suggesting that SgI peptides containing the LxxLL motif could prevent the function of SgI in the presence of zinc as well as in vivo data suggesting that SgI might correlate with induction of tumorigenesis.

15. SUBJECT TERMS

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	**b. ABSTRACT**	**c. THIS PAGE**	Unclassified	21	19b. TELEPHONE NUMBER *(include area code)*
Unclassified	Unclassified	Unclassified			

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

Table of Contents

1. INTRODUCTION

Semenogelins, mainly expressed and secreted by the seminal vesicle, are the major structural proteins in human semen containing a high concentration of Zn^{2+}, and their physiological functions have been well characterized. Specifically, semenogelins, upon binding to Zn^{2+}, play an important role in gel-like formation of the semen. After ejaculation, these proteins are degraded into smaller fragments by prostate-specific antigen (PSA), resulting in clotted gel liquefaction and release of the encased spermatozoa. Semenogelins are shown to be expressed in other male genital organs, such as the vas deferens, epididymis, and prostate, as well as in non-genital organs, suggesting their physiological role as modulators of zinc-dependent proteases throughout the body. Semenogelin I (SgI) expression has been detected in an androgen-sensitive prostate cancer line LNCaP, which is enhanced by zinc treatment, but not in other prostate cancer lines such as VCAP, CWR22Rv1, DU145, and PC3. We additionally demonstrated significantly higher levels of nuclear SgI expression in prostatic carcinoma than in non-neoplastic prostatic epithelium or high-grade prostatic intraepithelial neoplasia, which could also predict biochemical recurrence after radical prostatectomy. However, no functional analyses of semenogelins in pathological conditions have been reported and their roles in prostate cancer outgrowth remain uncertain. In this project, we aim to determine biological functions of SgI in prostate cancer, using preclinical models. In particular, we hypothesized that SgI could function as an androgen receptor (AR) co-activator in the presence of zinc and could thereby promote prostate cancer progression.

2. KEYWORDS

Androgen receptor; Co-activator; Prostate cancer; Prostate-specific antigen; Semenogelin; Seminal plasma protein; Seminal vesicle; Zinc

3. ACCOMPLISHMENTS

Major Goals

Task 1: To characterize semenogelins by testing their effects on the progression of prostate cancer *in vitro* (months 1-12: 100% completed)

Task 2: To assess the interactions between AR and semenogelins and the outcomes of their disruptions (months 13-36: 70% completed)

Task 3: To characterize semenogelins by testing their effects on the development and progression of prostate cancer *in vivo* (months 13-30: 50% completed)

Task 4: To assess the outcomes of disruption of AR-semenogelin interactions *in vivo* (months 25-36: 10% completed)

Accomplishments under the goals

(for Task 1) Using a lentivirus vector, we generated prostate cancer cell lines stably expressing SgI (*e.g.* LNCaP-SgI, VCaP-SgI, CWR22Rv1-SgI, DU145-SgI, PC3-SgI) and their vector controls. Similarly, silencing of SgI was achieved via short hairpin RNA (shRNA) (*e.g.* LNCaP-control-shRNA, LNCaP-SgI-shRNA). Overexpression or down-regulation of SgI protein in these stable cell lines was then confirmed (figure not shown). We also performed additional experiments required for publication as an original research article and finalized the data. This resulted in a publication in 2015 (please see section 6). As we anticipated in this task, this article included the data showing that: 1) prostate cancer cells did not normally secrete detectable amounts of SgI (Figure 1); 2) SgI protected AR-positive prostate cancer cells, but not AR-negative cells, from zinc that could strongly inhibit cell proliferation (Figure 2) and invasion (Figure 3); 3) SgI increased the levels of PSA expression in prostate cancer cells (Figure 4); and 4) SgI significantly induced androgen-mediated

AR transactivation in the presence of a high level of zinc in prostate cancer cells but rather marginally inhibited it in the presence of low levels of zinc (Figure 5). To investigate how SgI affects cell proliferation, we performed TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) assay and flow cytometry. However, SgI in the presence or absence of zinc did not significantly change apoptotic indices or G0/G1 population in LNCaP sublines. These findings, together with co-immunoprecipitation assay data described below (also see Figure 6), suggest that SgI promotes prostate cancer cell growth via functioning as an AR co-activator and protecting against zinc toxicity.

Figure 1. SgI protein expression and secretion in prostate cancer lines stably expressing SgI. Cell extracts

(**A**) or acetone-precipitated proteins in conditioned media (**B**) from LNCaP-V/SgI, DU145-V/SgI, PC3-V/SgI, and CWR22Rv1-V/SgI were analyzed on western blots, using an antibody to SgI (52 kDa) or β-actin (42 kDa). Fresh human seminal vesicle (SV) tissue was used as a positive control.

Figure 2. Cell viability of prostate cancer lines stably expressing SgI. CWR22Rv1-V/SgI (**A**), LNCaP-V/SgI (**B**), PC3-V/SgI (**C**), and DU145-V/SgI (**D**) were cultured in phenol red-free medium supplemented with 5% charcoal-stripped fetal bovine serum (FBS) in the presence or absence of 100 μM zinc and 1 nM dihydro-testosterone (DHT) for 96 hours. CWR22Rv1 (**E**) and DU145 (**F**) were cultured in conditioned medium (containing 10% normal FBS) derived from CWR22Rv1-V/SgI culture in the presence or absence of 100 μM zinc for 96 hours. Proliferation was assayed with MTT, and growth rates are presented relative to cell number in respective lines with mock treatment [lanes 1 (A-F) and 5 (A-D); set as 100%]. Each value represents the mean + SD of at least three determinations.


Figure 3. Cell invasion of prostate cancer lines stably expressing SgI. LNCaP-V/SgI cells cultured in the Matrigel-coated transwell chamber for 36 hours in the presence or absence of 300 μM zinc and 1 nM DHT were used for transwell assay. The number of invaded cells in five random fields was counted under a light microscope, using a 40x objective. Invasion ability is presented relative to that in each cell line with mock treatment (lane 1 or 5; set as 1-fold). Each value represents the mean + SD of at least three independent experiments.

Figure 4. PSA expression in prostate cancer lines expressing SgI. (**A**) LNCaP-V/SgI cells cultured in phenol red-free medium supplemented with 5% charcoal-stripped FBS in the presence or absence of 300 μM zinc and 1 nM DHT for 48 hours were subjected to a quantitative reverse transcription-polymerase chain reaction. Expression of *PSA* gene was normalized to that of *GAPDH*. Transcription amount is presented relative to that of mock treatment in each cell line (lane 1 or 5; set as 1-fold). Each value represents the mean + SD from at least three independent experiments. CWR22Rv1 cells (**B**) transiently transfected with pSG5 or pSG5-SgI were cultured in phenol red-free medium supplemented with 5% charcoal-stripped FBS in the presence or absence of 100 μM zinc and 1 nM DHT for 48 hours, and LNCaP-V/SgI cells (**C**) were similarly cultured with 300 μM zinc ± 1 nM DHT for 48 hours, as indicated. Cell extracts were then analyzed on western blots, using an antibody to PSA (33 kDa) or β-actin.


Figure 5. The effects of SgI on AR transcriptional activity in prostate cancer cells. PC3 cells were co-transfected with pSG5-AR, MMTV-Luc, pRL-TK, and either pSG5 or pSG5-SgI (AR:SgI = 1:5), and cultured in phenol red-free medium supplemented with 5% charcoal-stripped FBS along with mock (ethanol), zinc [(**A**) 0 μM; (**B**) 15 μM; (**C**) 100 μM], and/or 1 nM DHT for 24 hours. Similarly, CWR22Rv1 cells were co-transfected with MMTV-Luc, pRL-TK, and either pSG5 or pSG5-SgI, and treated with mock (ethanol) or 1 nM DHT in the absence (**D**) or presence (**E**) of 100 μM zinc for 24 hours. The luciferase activity is presented relative to that of mock treatment (first lanes; set as 1-fold). Each value represents the mean + SD of at least three determinations.

(for Task 2a: Nuclear receptor-semenogelin interactions) We first assessed the interactions between AR and SgI. Co-immunoprecipitation assay clearly demonstrated a formation of AR (wild-type, T877A mutant)-SgI complex especially in the presence of androgen (Figure 6). Nonetheless, we failed to confirm AR-SgI interactions by mammalian two-hybrid assay in cells transfected with Gal4-DBD-AR, VP16-SgI, and pG5-Luc reporter and treated with androgen. Additionally, in these assays, SgI did not interact with estrogen receptor-α, estrogen receptor-β, or glucocorticoid receptor.

Figure 6. Co-precipitation of AR and SgI. Cell lysates from 293T transfected with pSG5-AR and pSG5-SgI (**A**) or LNCaP (**B**) treated with mock (ethanol) or 1 nM DHT were incubated with an anti-AR polyclonal antibody or normal rabbit IgG and then with A/G-agarose beads. The complex was resolved on a 10% SDS-polyacrylamide gel and blotted with an anti-AR or anti-SgI antibody.

(for Task 2b: AR N/C-terminus interaction) Mammalian two-hybrid assay was again used to determine the influence of SgI on AR N/C interaction. While AR N/C interactions were confirmed, no significant effect of SgI on these interactions was seen (Figure 7). Furthermore, SgI overexpression in LNCaP and VCAP cells did not significantly affect the expression and nuclear translocation of AR

detected by Western blotting and immunofluorescence, respectively.

Figure 7. The effects of SgI on AR N/C interactions in prostate cancer cells. PC3 cells were co-transfected with GAL4-AR-C, VP16-AR-N or VP16-vector, pG5-Luc, pRL-TK, and pSG5 or pSG5-SgI, and cultured for 24 hours. The luciferase activity is presented relative to that of VP16-vector (no VP16-AR-N/SgI; first lane, set as 1-fold). Each value represents the mean + SD of at least three determinations.

(for Task 2d: Identification of AR-interaction domain in semenogelins) To identify minimal AR-interaction domain of SgI, the LxxLL (L = leucine; x = any amino acids) motif that has been reported to be essential and sufficient for mediating the interactions between AR and some AR co-regulators was mutated to

LxxAA (A = alanine) by a site-directed mutagenesis method (Figure 8). This construct was used for further analyses.

Figure 8. Sequencing of wild-type SgI containing the LxxLL motif and a mutant SgI containing the LxxAA motif.

Co-immunoprecipitation assay in prostate cancer cells revealed that the mutant SgI containing the LxxAA motif no longer interacted with AR in the presence or absence of androgen (Figure 9). Mammalian two-hybrid assay also showed no interactions between AR and the mutant SgI, while there was no significant increase in luciferase activity in cells transfected with Gal4-DBD-AR, VP16-SgI (wild-type), and pG5-Luc.

Figure 9. Co-immunoprecipitation of AR and wild-type SgI or a mutant SgI. Cell lysates from PC3 transfected with AR and either wild-type or mutant SgI and treated with ethanol (mock) or 1 nM DHT was incubated with an anti-SgI antibody and was then immunoblotted with an anti-AR or anti-SgI antibody.

The above findings strongly suggest that the motif in SgI is critical for in AR-SgI interactions. We next constructed several SgI peptides (*i.e.* 18-22 amino acids) including the LxxLL (wild-type) or LxxAA (mutant) motif. Then, we performed luciferase assay to assess the effects of SgI peptides on AR transcriptional activity. In LNCaP cells with endogenous SgI cultured with 100 μM zinc, the expression of a wild-type SgI peptide (lanes 2 *vs.* 3), but not a mutant SgI peptide (lanes 2 *vs.* 4), resulted in a significant decrease in androgen-induced AR transactivation (Figure 10A). As expected, SgI peptides showed no significant effects on AR transactivation (lanes 2 *vs.* 3 or 4) in LNCaP cells cultured without zinc (Figure 10B) or LNCaP-SgI-shRNA cells cultured with zinc (Figure 10C). In addition, lower induction of AR transcription by DHT (lanes 1 *vs.* 2) was observed in LNCaP-control-shRNA cells with no additional zinc (Figure 10B) or LNCaP-SgI-shRNA (Figure 10C), compared with LNCaP-control-shRNA cells with zinc (Figure 10A).

Figure 10. The effects of SgI peptides on AR transcriptional activity in prostate cancer cells. LNCaP (**A, B**) or LNCaP-SgI-shRNA (**C**) cells expressed with wild-type (WT) or mutant (MT) SgI peptide were co-transfected with MMTV-Luc and pRL-TK and cultured in phenol red-free medium supplemented with 5% charcoal-stripped FBS along with mock (ethanol) or 1 nM DHT as well as zinc [(**A, C**) 100 μM; (**B**) 0 μM] for 24 hours. The luciferase activity is presented relative to that of mock treatment (first lanes; set as 1-fold). Each value represents the mean + SD of at least three determinations. *$P < 0.05$ (*vs.* DHT only).

These findings suggest that wild-type SgI peptide is able to prevent the function of SgI as an AR co-activator in prostate cancer cells in the presence of zinc. We will further assess the effects of SgI peptides on PSA expression, cell viability/migration/ invasion, apoptosis, and cell cycle in prostate cancer cells with or without expressing SgI and culturing zinc.

(for Task 3) As described above, we established a LNCaP subline stably expressing SgI-shRNA (LNCaP-SgI-shRNA) and a VCAP subline stably expressing SgI (VCAP-SgI), as well as their control lines. Using LNCaP-control-shRNA versus LNCaP-SgI-shRNA cell lines, we preliminarily compared tumor formation in an animal model. Each cell line mixed with Matrigel was inoculated subcutaneously into immunocompromised male mice, and tumor formation was monitored. SgI silencing slightly delayed tumor formation, compared with controls, but the difference did not reach statistical significance by log-rank test, potentially due to relatively small number of mice in each group (Figure 11; $P = 0.084$). In contrast, there was little difference in tumor formation between VCAP-control and VCAP-SgI ($P = 0.358$).

Figure 11. Effects of SgI on tumor formation in a mouse xenograft model. LNCaP-control-shRNA or LNCaP-SgI-shRNA were suspended and mixed with Matrigel (1 x 10^6 cells/100 μL), and were subcutaneously implanted into the flank of 6-week-old male NOD-SCID mice (n = 5 in each group). The endpoint for this study was tumor formation (exceeding 40 mm^3 in its estimated volume [by the following formula: (short diameter)^2 × (longest diameter) × 0.5]).

We will repeat the xenograft experiments (n = at least 8 in each group) described above. After assessing the timing of tumor formation, we will continue to compare tumor growth between SgI-positive versus SgI-negative xenografts.

(for Task 4) Using LNCaP-control/SgI-shRNA cell lines as well as the peptides described above, we will assess the efficacy of SgI peptides on tumor growth in a mouse xenograft model.

Opportunities for training and professional development

Nothing to report.

How were the results disseminated to communities of interest?

Nothing to report.

Plan to do during the next reporting period to accomplish the goals

We will perform the remaining of the proposed experiments (Tasks 2, 3, and 4) to accomplish the goals. These experiments are critical particularly to determine the clinical relevance of our *in vitro* findings and address the feasibility of future therapeutic intervention.

4. IMPACT

Principal disciplines

Androgens act upon their binding to androgen receptor whose signals are further activated by co-activators. It is also well known that androgens play a key role in the development and progression of prostate cancer. The impact of our findings may be two-fold. First, a seminal plasma protein, semenogelin I, was found to serve as an androgen receptor co-activator only in the presence of zinc and could thereby promote prostate cancer outgrowth. Second, we demonstrated molecular evidence to answer why prostate cancer tissue contains high levels of zinc which by itself was known to have a strong inhibitory effect on tumor growth. These findings, together with our further work on this project, will help provide an effective treatment strategy for advanced prostate cancer.

Other disciplines

Nothing to report.

Technology transfer

Nothing to report.

Society beyond science and technology

Nothing to report.

5. CHANGES/PROBLEMS

Nothing to report.

6. PRODUCTS

Journal publications

Ishiguro H, Izumi K, Kashiwagi E, Zheng Y, Li Y, Kawahara T, Miyamoto H: Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity. *Am J Cancer Res* 5(2): 738-747, 2015.

Presentations

Ishiguro H, Izumi K, Zheng Y, Kashiwagi E, Kawahara T, Miyamoto H: Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity. American Urological Association 109th Annual Meeting, May 2014, Orlando, Florida [*J Urol* 191 (Suppl 4S): e325, 2014].

Kashiwagi E, Ishiguro H, Izumi K, Zheng Y, Li Y, Kawahara T, Miyamoto H: Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity.* 10th Annual Johns Hopkins Prostate Cancer Research Day at Mt. Washington Conference Center, Baltimore, Maryland (February 21, 2015).

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

Individuals who have worked on the project

Hiroshi Miyamoto, MD, PhD
Project role: PI
Person month worked: 1.65 (5% effort)
Contribution to the project: As the PI Dr. Miyamoto has been responsible for overseeing all aspects of the project, including designing the experiments, analyzing the data, and writing project reports and manuscripts.
Other funding support: Department of Defense Prostate Cancer Research Program (W81XWH-09-1-0305 as a PI); Department of Defense Prostate Cancer Research Program (W81XWH-10-2-0056 as a co-investigator); Astellas Scientific and Medical Affairs, Inc. (as a PI); NIH/NCI (R01 CA155477-01 as a consultant)

Hitoshi Ishiguro, PhD
Project role: Postdoctoral fellow
Person month worked: 1

Contribution to the project: Dr. Ishiguro has performed most of the proposed experiments during month 1.
Other funding support: None

Eiji Kashiwagi, MD, PhD
Project role: Postdoctoral fellow
Person month worked: 17
Contribution to the project: Dr. Kashiwagi has performed most of the proposed experiments during months 2-18.
Other funding support: None

Hiroki Ide, MD
Project role: Postdoctoral fellow
Person month worked: 15
Contribution to the project: Dr. Ide has performed most of the proposed experiments during months 19-33.
Other funding support: None

Bin Han, MD, PhD
Project role: Postdoctoral fellow
Person month worked: 1
Contribution to the project: Dr. Han has performed co-immunoprecipitation assay and related experiments.
Other funding support: None

Change in the active other support of the PI

Department of Defense Prostate Cancer Research Program Physician Research Training Award (W81XWH-09-1-0305 to the PI) and Astellas Scientific and Medical Affairs, Inc. (to the PI) have closed on February 2, 2015 and October 13, 2015, respectively.

Other organizations involved as partners

Nothing to report.

8. SPECIAL REPORTING REQUIREMENTS

Not applicable.

9. APPENDICES

N/A

Original Article
Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity

Hitoshi Ishiguro[1,2*], Koji Izumi[2*], Eiji Kashiwagi[1*], Yichun Zheng[1,2,3], Yi Li[2,3], Takashi Kawahara[1,2], Hiroshi Miyamoto[1,2]

[1]Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; [2]Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA; [3]Department of Urology, 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. *Equal contributors.

Abstract: A seminal plasma protein, semenogelin I (SgI), contributes to sperm clotting, upon binding to Zn^{2+}, and can be proteolyzed by prostate-specific antigen (PSA), resulting in release of the trapped spermatozoa after ejaculation. In contrast, the role of SgI in the development and progression of any types of malignancies remains largely unknown. We previously demonstrated that SgI was overexpressed in prostate cancer tissues and its expression was enhanced by zinc treatment in LNCaP cells. In the current study, using cell lines stably expressing SgI, we investigated its biological functions, in conjunction with zinc, androgen, and androgen receptor (AR), in prostate cancer. Zinc, without SgI, inhibited cell growth of both AR-positive and AR-negative lines. Co-expression of SgI prevented zinc inhibiting dihydrotestosterone-mediated proliferation of AR-positive cells, whereas SgI and/or dihydrotestosterone showed marginal effects in AR-negative cells. Similar effects of SgI overexpression in LNCaP on dihydrotestosterone-induced cell invasion, such as its significant enhancement with zinc, were seen. Overexpression of SgI in LNCaP and CWR22Rv1 cells also augmented dihydrotestosterone-mediated PSA expression (mRNA, protein) in the presence of zinc. However, culture in the conditioned medium containing secreted forms of SgI failed to significantly increase cell viability with or without zinc. In luciferase reporter gene assays, SgI showed even slight inhibitory effects (8% and 15% decreases in PC3 and CWR22Rv1, respectively) at 0 μM zinc and significant stimulatory effects (2.1- and 3.2-fold) at 100 μM zinc on dihydrotestosterone-enhanced AR transactivation. Co-immunoprecipitation then demonstrated dihydrotestosterone-induced physical interactions between AR and SgI. These results suggest that intracellular SgI, together with zinc, functions as an AR coactivator and thereby promotes androgen-mediated prostate cancer progression.

Keywords: Androgen receptor, prostate cancer, prostate-specific antigen, semenogelin, zinc

Introduction

The signaling pathway of androgen receptor (AR), a member of the nuclear receptor superfamily, plays a critical role in the growth of not only androgen-sensitive prostate cancer cells but also most cells from clinically defined androgen-independent prostate cancer. In particular, co-regulatory proteins that mediate receptor transcriptional activation or repression have been suggested to modulate the events of tumor progression. Various nuclear receptor coregulators as well as selective coactivators that enhance AR-mediated transcriptional activity have indeed been isolated [1-4].

The prostate accumulates the highest level of zinc (3,000-4,500 μM in normal peripheral zone) in the body and secretes high amounts of zinc in the prostatic fluid (8,000-10,000 μM) [5]. A significant decrease in zinc levels is seen in prostate cancer tissue, yet the concentrations (400-800 μM) remain relatively high, compared with those in other soft tissue (200-400 μM) or blood plasma (15 μM) [5, 6]. Of note, however, zinc (*e.g.* 100 μM in PC3 culture) has been shown to considerably inhibit the proliferation of prostate cancer cells [7-10]. To our knowledge, there is no definitive molecular evidence explaining the enigma of high concentrations of cytotoxic zinc in prostate cancer tissue. Furthermore, there are controversial epidemio-

logical data on the relationship between zinc intake and the risk of prostate cancer [5, 11].

Semenogelins, mainly expressed and secreted by the seminal vesicle, are the major structural proteins in human semen containing a high concentration of Zn^{2+}, and their physiological functions have been well characterized. Specifically, semenogelins, upon binding to Zn^{2+}, play an important role in gel-like formation of the semen [12]. After ejaculation, these proteins are degraded into smaller fragments by prostate-specific antigen (PSA), resulting in clotted gel liquefaction and release of the encased spermatozoa [13]. Semenogelins have also been shown to inhibit the protease activity of PSA [14]. Semenogelins are expressed in other male genital organs, such as the vas deferens, epididymis, and prostate, as well as in non-genital organs, suggesting their physiological role as modulators of zinc-dependent proteases throughout the body [15, 16]. Semenogelin I (SgI) expression has been detected in an androgen-sensitive prostate cancer line LNCaP, which is enhanced by zinc treatment, but not in other prostate cancer lines such as CWR22Rv1, DU145, and PC3 [15, 17]. We additionally demonstrated significantly higher levels of nuclear SgI expression in prostatic carcinoma than in non-neoplastic prostatic epithelium or high-grade prostatic intraepithelial neoplasia (PIN), which could also predict biochemical recurrence after radical prostatectomy [17, 18]. However, no functional analyses of semenogelins in pathological conditions have been reported and their roles in prostate cancer growth remain uncertain. In the current study, we aim to determine the biological significance of SgI, in conjunction with zinc, androgen, and AR, in prostate cancer cells.

Materials and methods

Plasmids

The entire coding region of SgI amplified using Phusion-High Fidelity DNA polymerase (Thermo Fisher Scientific) was subcloned into pSG5 [17] and lentivirus pWPI vector [19]. pSG5-AR, pGL3-MMTV-luciferase, and pRL-TK have been used in our previous studies [20, 21].

Antibodies and chemicals

Anti-AR (N-20), anti-SgI (E-15), and anti-β-actin (R-22) antibodies were purchased from Santa Cruz Biotechnology. An anti-PSA antibody (A0562) was purchased from Dako. Dihydrotestosterone (DHT) and $ZnCl_2$ were from Sigma-Aldrich and Alfa Aesar, respectively.

Cell lines

CWR22Rv1, LNCaP, PC3, and DU145 cell lines originally obtained from the American Type Culture Collection and recently authenticated by the institutional core facility were maintained with RPMI 1640 (Mediatech) supplemented with 10% fetal bovine serum (FBS). To generate cell lines stably expressing SgI, pWPI-SgI, along with GFP expressing vector, was co-transfected, using GeneJuice transfection reagent (Novagen), and GFP expressing cells were selected.

MTT assay

Cell viability was assessed, using methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. Cells (1-3 × 10^3/well) seeded in 96-well tissue culture plates were incubated in the presence or absence of zinc and DHT. The media were refreshed every 48 hours. After 96 hours of treatment, 10 μL MTT stock solution (5 mg/mL; Sigma) was added to each well with 100 μL of medium for 4 hours at 37°C. The medium was replaced with 100 μL dimethyl sulfoxide, followed by incubation for 5 minutes at room temperature. The absorbance at a wavelength of 570 nm with background subtraction at 655 nm was then measured.

Transwell invasion assay

Cell invasiveness was determined, using Matrigel-coated transwell chambers (Costar), as described previously [21]. Briefly, cells (5 × 10^4) in 100 l of serum-free medium were added to the upper chamber of the transwell, while 600 l of medium containing 5% FBS was added to the lower chamber. The media in both chambers contained ethanol, zinc, and/or DHT. After incubation for 36 hours at 37°C in a CO_2 incubator, invaded cells were fixed, stained with 0.1% crystal violet, and counted.

Reverse transcription (RT)-polymerase chain reaction (PCR)

Total RNA (0.5 μg) was isolated from the cultured cells, using TRIzol (Invitrogen), and reverse transcribed with oligo (dT) primers and Omniscript reverse transcriptase (Qiagen), as

Figure 1. Sgl protein expression and secretion in prostate cancer lines stably expressing Sgl. Cell extracts (A) or acetone-precipitated proteins in conditioned media (serum-free, no additional zinc) (B) from LNCaP-V/Sgl, DU145-V/Sgl, PC3-V/Sgl, and CWR22Rv1-V/Sgl were analyzed on western blots, using an antibody to Sgl (52 kDa) or β-actin (42 kDa). Fresh human seminal vesicle (SV) tissue was used as a positive control.

described previously [19, 21, 22]. Real-time PCR was then performed, using RT^2 SYBR® Green FAST Mastermix (Qiagen) for iCycler (Invitrogen). The following primer pairs were used for RT-PCR: *PSA* (forward, 5'-GCAGTC-TGCGGCGGTGTTCT-3'; reverse, 5'-GCGGGTG-TGGGAAGGTGTGG-3'), and *GAPDH* (forward, 5'-CTCCTCCACCTTTGACGCTG-3'; reverse, 5'-C-ATACCAGGAAATGAGCTTGACAA-3').

Western blot

Protein extraction and western blotting were performed, as described previously [19-22] with minor modifications. Briefly, equal amounts of protein obtained from cell extracts were subjected to SDS-PAGE, transferred to polyvinylidene difluoride membranes electronically, blocked, and incubated with a specific primary antibody. The membrane was then incubated with a HRP-conjugated secondary antibody, and specific signals were detected, using chemiluminescent substrate kit (Thermo Fisher Scientific).

Luciferase assay

Cells were transfected with an androgen response element-reporter (MMTV-Luc), pSG5 or pSG5-Sgl, and a control reporter (pRL-TK), using GeneJuice. pSG5-AR was also transfected into PC3 cells. Then, the cells were treated with zinc and/or DHT for 24 hours, and the luciferase activity was determined in the cell lysates, using a Dual-Luciferase Reporter Assay

kit (Promega) and luminometer (FLUOstar Omega, BMG Labtech).

Co-immunoprecipitation

The cell lysates (500 g) were incubated with 2 g anti-AR antibody or normal rabbit IgG for 16 hours at 4°C with agitation. Protein A/G-agarose beads were then added, and binding proteins were eluted. The eluted proteins were analyzed by western blot with an anti-AR or anti-Sgl antibody.

Statistical analysis

Student's *t*-test was used to analyze differences in variables with a continuous distribution. *P* values less than 0.05 were considered statistically significant.

Results

Expression of Sgl in prostate cancer cells and conditioned media

Using a lentivirus vector, we generated prostate cancer cell lines stably expressing Sgl. Overexpression of Sgl protein in these stable cell lines and relatively weak expression of endogenous Sgl in LNCaP were confirmed (**Figure 1A**). To detect a secreted form of Sgl, western blot was also performed in acetone-precipitated medium where each stable line was cultured under serum-free conditions for 24 hours. No signal was detected in conditioned medium after culturing Sgl-weakly positive (*i.e.* no additional zinc; RPMI 1640 with 10% FBS contains approximately 3.8 μM zinc [23]) LNCaP-Vector (V) as well as three Sgl-negative control lines (**Figure 1B**). In contrast, Sgl was found to be secreted in the supernates where Sgl-overexpressing cells were cultured. These results suggest that, in accordance with our immunohistochemistry data in radical prostatectomy specimens [18], prostate cancer cells do not normally secrete detectable amounts of Sgl.

Induction of prostate cancer progression by Sgl with zinc

To see if Sgl affects prostate cancer cell proliferation, we performed MTT assay in the stable cells. Each line was cultured for 4 days in the presence or absence of DHT (1 nM) and zinc (100 μM). As expected, zinc treatment signifi-

Figure 2. Cell viability of prostate cancer lines stably expressing Sgl. CWR22Rv1-V/Sgl (A), LNCaP-V/Sgl (B), PC3-V/Sgl (C), and DU145-V/Sgl (D) were cultured in phenol red-free medium supplemented with 5% charcoal-stripped FBS in the presence or absence of 100 µM zinc and 1 nM DHT for 96 hours. CWR22Rv1 (E) and DU145 (F) were cultured in conditioned medium (containing 10% normal FBS) derived from CWR22Rv1-V/Sgl culture in the presence or absence of 100 µM zinc for 96 hours. Proliferation was assayed with MTT, and growth rates are presented relative to cell number in respective lines with mock treatment [lanes 1 (A-F) and 5 (A-D); set as 100%]. Each value represents the mean + SD of at least three determinations.

cantly inhibited the growth of all control lines (**Figure 2**; 21-45% decrease; lanes 1 *vs.* 2) except LNCaP-V. In AR-positive CWR22Rv1-derived cells (**Figure 2A**), DHT increased the growth by 12-13% without zinc treatment (lanes 1 *vs.* 3 and 5 *vs.* 7). In the presence of zinc, DHT showed a similar induction rate in CWR22Rv1-V (14% increase; lanes 2 *vs.* 4), whereas overexpression of Sgl resulted in a statistically significant increase in the growth rate (27%; lanes 6 *vs.* 8; *p* = 0.034). Thus, zinc

only marginally decreased cell growth of CWR22Rv1-Sgl (lanes 5 *vs.* 6 and 7 *vs.* 8). In LNCaP cells with endogenous Sgl (LNCaP-V; **Figure 2B**), zinc treatment did not decrease, rather marginally increased, the growth in the absence (lanes 1 *vs.* 2) or presence (lanes 3 *vs.* 4) of DHT. DHT increased the growth of LNCaP-V without (62%; lanes 1 *vs.* 3; *p* = 0.009) or with (52%; lanes 2 *vs.* 4; *p* = 0.014) zinc as well as that of LNCaP-Sgl without (66%; lanes 5 *vs.* 7; *p* = 0.036) or with (82%; lanes 6 *vs.* 8; *p* = 0.018)

Figure 3. Progression of prostate cancer lines stably expressing Sgl. (A) LN-CaP-V/Sgl cells cultured in the Matrigel-coated transwell chamber for 36 hours in the presence or absence of 300 µM zinc and 1 nM DHT were used for transwell assay. The number of invaded cells in five random fields was counted under a light microscope, using a 40x objective. Invasion ability is presented relative to that in each cell line with mock treatment (lane 1 or 5; set as 1-fold). Each value represents the mean + SD of at least three independent experiments. (B) LNCaP-V/Sgl cells cultured in phenol red-free medium supplemented with 5% charcoal-stripped FBS in the presence or absence of 300 µM zinc and 1 nM DHT for 48 hours were subjected to a quantitative RT-PCR. Expression of *PSA* gene was normalized to that of *GAP-DH*. Transcription amount is presented relative to that of mock treatment in each cell line (lane 1 or 5; set as 1-fold). Each value represents the mean + SD from at least three independent experiments. CWR22Rv1 cells (C) transiently transfected with pSG5 or pSG5-Sgl were cultured in phenol red-free medium supplemented with 5% charcoal-stripped FBS in the presence or absence of 100 µM zinc and 1 nM DHT for 48 hours, and LNCaP-V/Sgl cells (D) were similarly cultured with 300 µM zinc ± 1 nM DHT for 48 hours, as

indicated. Cell extracts were then analyzed on western blots, using an antibody to PSA (33 kDa) or β-actin.

zinc. Thus, co-expression of Sgl in the presence of zinc appeared to induce androgen-mediated proliferation of AR-positive prostate cancer cells and, more importantly, protected the cells from cytotoxic effects of zinc. In AR-negative PC3-derived (**Figure 2C**) and DU145-derived (**Figure 2D**) cells, DHT treatment and Sgl overexpression showed only marginal effects on their growth (< 10% changes). Because semenogelins are secreted proteins [12], we further tested whether secreted forms of Sgl induced prostate cancer cell proliferation. MTT assay was again performed in CWR22Rv1 (**Figure 2E**) and DU145 (**Figure 2F**) cells incubated in the conditioned medium derived from CWR22Rv1-V/Sgl culture. In these parental lines, the secreted form of Sgl did not significantly affect cell viability in the absence (lanes 1 *vs.* 3) or presence (lanes 2 *vs.* 4) of zinc.

To investigate whether Sgl promotes tumor invasion, a transwell invasion assay was performed in the stable LNCaP lines (**Figure 3A**). DHT similarly induced cell invasion of LN-CaP-V without (35% increase; lanes 1 *vs.* 2; *p* = 0.042) or with (48% increase; lanes 3 *vs.* 4; *p* = 0.009) zinc or LNCaP-Sgl without zinc (48% increase; lanes 5 *vs.* 6; *p* = 0.026). In contrast, in LNCaP-Sgl with zinc, the invasiveness was more significantly increased by DHT (2.8-fold over mock treatment; lanes 7 *vs.* 8; *p* = 0.006). Thus, significant induction of the DHT-mediated

Figure 4. The effects of Sgl on AR transcriptional activity in prostate cancer cells. PC3 cells were co-transfected with pSG5-AR, MMTV-Luc, pRL-TK, and either pSG5 or pSG5-Sgl (AR:Sgl = 1:5), and cultured in phenol red-free medium supplemented with 5% charcoal-stripped FBS along with mock (ethanol), zinc [(A) 0 μM; (B) 15 μM; (C) 100 μM], and/or 1 nM DHT for 24 hours. Similarly, CWR22Rv1 cells were co-transfected with MMTV-Luc, pRL-TK, and either pSG5 or pSG5-Sgl, and treated with mock (ethanol) or 1 nM DHT in the absence (D) or presence (E) of 100 μM zinc for 24 hours. The luciferase activity is presented relative to that of mock treatment (first lanes; set as 1-fold). Each value represents the mean + SD of at least three determinations.

invasive properties by endogenous Sgl (lanes 2 vs. 4; 19% increase) or exogenous Sgl overexpression (lanes 6 vs. 8; 88% increase) with versus without addition of zinc was seen.

We next determined whether Sgl regulated the expression of PSA, an androgen-inducible AR target and also known to proteolyze Sgl in semen [12, 13], in prostate cancer cells. A quantitative RT-PCR showed that DHT treatment, in the absence of additional zinc, increased endogenous *PSA* expression over mock treatment by 3.4-fold (lanes 1 vs. 2; p <

0.001)/3.8-fold (lanes 5 vs. 6; p = 0.009) in LNCaP-V/Sgl (**Figure 3B**), respectively. In the presence of 300 μM zinc, DHT increased *PSA* expression by 4.7-fold (lanes 3 vs. 4; p = 0.004)/7.1-fold (lanes 7 vs. 8; p = 0.003) in LNCaP-V/Sgl, respectively. The difference in DHT-mediated *PSA* expression in LNCaP-Sgl with versus without zinc was also statistically significant (lanes 6 vs. 8; 1.8-fold). Similarly, western blots in CWR22Rv1 cells cultured with 100 μM zinc (**Figure 3C**) and LNCaP stable cells cultured with 300 μM zinc (**Figure 3D**) showed that overexpression of Sgl resulted in consider-

Figure 5. Co-precipitation of AR and SgI. Cell lysates from 293T transfected with pSG5-AR and pSG5-SgI (A) or LNCaP (B) treated with mock (ethanol) or 1 nM DHT were incubated with an anti-AR polyclonal antibody or normal rabbit IgG and then with A/G-agarose beads. The complex was resolved on a 10% SDS-polyacrylamide gel and blotted with an anti-AR or anti-SgI antibody.

able increases in DHT-mediated PSA expression. However, no significant additive effects of SgI on PSA protein expression were seen in these cell lines when cultured without additional zinc (figure not shown).

Enhancement of AR transcriptional activity by SgI

To assess the effect of SgI on androgen-mediated AR transactivation, luciferase activity was determined in PC3 cells transfected with AR, SgI, and an androgen response element-reporter plasmid, and treated with different concentrations of zinc and 1 nM DHT. DHT increased AR transcription by 17-fold (0 μM zinc; **Figure 4A**), 12-fold (15 μM zinc; **Figure 4B**), and 10-fold (100 μM zinc; **Figure 4C**), as compared with respective mock treatments. Thus, zinc reduced androgen-enhanced AR transactivation in a dose-dependent manner. SgI showed a slight inhibitory effect (15% decrease at 0 μM zinc; **Figure 4A**) or a slight stimulatory effect (31% increase at 15 μM zinc; **Figure 4B**) on DHT-induced AR transcription. In contrast, in the presence of 100 μM zinc, SgI further induced DHT-mediated AR transcription by 3.2-

fold (**Figure 4C**). Induction of zinc/DHT-mediated AR transcription by SgI (2.1-fold) was confirmed in CWR22Rv1, while SgI did not significantly affect AR transactivation without additional zinc (8% decrease) (**Figure 4D**, **4E**). These results suggest that SgI functions as an AR coactivator in the presence of zinc in prostate cancer cells.

Interaction between AR and SgI

AR coregulators modulate AR-mediated transcriptional activity by interacting with AR [1-3]. To verify the interaction between AR and SgI, co-immunoprecipitation assay, using cell lysates with (293T) or without (LNCaP) transfection of AR and SgI, was performed. Using an anti-AR antibody, we precipitated the AR binding protein complex in the protein lysate. We then proved that AR-SgI form a complex, especially in the presence of DHT, in 293T (**Figure 5A**) and LNCaP (**Figure 5B**) cells.

Discussion

While functions of semenogelins have been thoroughly characterized in physiological environment especially in the male reproductive system, little is known about their roles in human malignancies. Our previous immunohistochemical studies showed that both SgI and semenogelin II (SgII) were overexpressed in prostate cancer tissue specimens and that patients with SgI-positive tumor, but not SgII-positive or SgII-negative tumor, had a significantly higher risk of recurrence following radical prostatectomy [17, 18]. Furthermore, transient transfection of SgI, but not SgII, into AR-positive/semenogelin-negative CWR22Rv1 resulted in an increase in cell proliferation in the presence of a high level of zinc [17]. Based on these findings, we hypothesized that SgI, in conjunction with zinc, androgen, and AR, promoted prostate cancer progression. In the present study, we tested our hypothesis in prostate cancer cell lines.

Experimental evidence indicates an inhibitory role of zinc in the development and progression of prostate cancer. However, it remains controversial whether zinc supplements reduce the risk of prostate cancer [5, 11]. In addition, the molecular basis for why prostate cancer tissue contains relatively high concentrations of cytotoxic zinc is poorly understood, although altera-

tions of zinc transporters in prostate cancer cells have been suggested to prevent zinc accumulation [24, 25]. Previous in vitro studies have shown that higher concentrations of zinc are required to inhibit cell proliferation of LNCaP (250-1000 µM), compared with PC3 (100 µM) [7, 8]. We confirmed these findings and further demonstrated that 100 µM zinc could inhibit cell growth of other SgI-negative prostate cancer lines. Thus, endogenous SgI in LNCaP may protect the cells against inhibitory effects of zinc. Interestingly, co-expression of SgI only in AR-positive CWR22Rv1 cells resulted in prevention from zinc cytotoxicity. SgI also induced androgen-mediated prostate cancer cell invasion and PSA expression only in the presence of zinc. These results suggest that SgI may require not only zinc, as in the case of its physiological action [12-16], but also AR to function as a modulator of prostate cancer outgrowth. Moreover, the presence of SgI in prostate cancer cells can be a reason for zinc accumulation in tumors.

It is well documented that co-regulatory proteins modulate nuclear receptor-mediated transcriptional activity by interacting with the receptor [1-4]. We here showed that SgI interacted with AR and enhanced androgen-induced AR transactivation in prostate cancer cells, indicating that SgI is an AR coactivator. Again, a high level of zinc was most likely required for this newly recognized function of SgI. Although a variety of general or specific AR coactivators have been identified, physiological functions of these coactivators are largely unknown and their characterization has not yet led to the development of new therapeutic options in patients with prostate cancer [26, 27]. It has been expected that suppression of coactivator actions or interruption of AR-coactivator interactions results in prostate cancer regression at any stages because castration-resistant tumors usually remain AR-dependent for their growth. Importantly, as aforementioned, physiological roles of semenogelins as seminal plasma proteins have been extensively studied. SgI was also shown to be highly expressed in prostate cancer cells [15, 17, 18]. In addition, because PSA is known to physiologically degrade semenogelins [13], elevated SgI may result in a further increase in PSA levels to attempt to target semenogelins. As a result, down-regulation of SgI expression, compared with other AR coactivators, may more effectively inhibit prostate cancer progression that can be facilitated by PSA itself via enhancing an AR

coactivator ARA70-regulated AR transactivation [28]. The cytotoxic activity of zinc may also become distinct with SgI down-regulation. Further analyses of SgI in prostate cancer are necessary to credential a new therapeutic target.

The current results suggest that cellular SgI, but not its secreted forms, plays an important role in prostate cancer outgrowth. However, semenogelins are essentially secreted proteins, mainly derived from the seminal vesicle. Indeed, we detected SgI signals in secreted materials, in addition to cellular immunoreactivity, in prostatectomy specimens [18]. Although moderate to strong SgI signals were seen in the majority of benign (97%) or PIN (98%) glands where the secretions were present, intraluminal secretions in carcinoma glands were uncommonly (13%) immunoreactive and their signals, if present, were mostly weak. These findings suggested that, in contrast to benign or PIN cells, carcinoma cells did not generally secrete a large amount of SgI. We confirmed this by demonstrating the failure to detect SgI signals in the conditioned medium after culturing control LNCaP with endogenous SgI and other SgI-negative prostate cancer cell lines in our western blotting. Instead, increased levels of serum semenogelins were detected in 4 of 13 patients with lung cancer, although their functions in lung carcinogenesis and tumor progression were not studied [29]. Again, in our assays, a secreted form of SgI present in the conditioned medium where CWR22Rv1-SgI was cultured failed to induce the proliferation of parental CWR22Rv1 cells even in the presence of zinc. It is still possible that SgI secreted by benign prostate or PIN cells as well as tissues other than the prostate exerts an influence on prostate cancer growth with or without involving zinc and AR.

In conclusion, our current data indicating that intracellular SgI in the presence of zinc functions as an AR coactivator and promotes the growth of prostate cancer cells provide its novel role in tumor progression. Particularly, SgI protects the cells against zinc cytotoxicity, which may explain why prostate cancer tissue contains high levels of zinc.

Acknowledgements

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Hiroshi Miyamoto, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, 600 North Wolfe Street, Marburg 148, Baltimore, MD, USA. Tel: 410-614-1442; E-mail: hmiyamo1@jhmi.edu

References

[1] Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 265-271.

[2] Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004; 10: 2208-2219.

[3] Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007; 120: 719-733.

[4] Lonard DM, O'Malley BW. Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol 2012; 8: 598-604.

[5] Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 2006; 5: 17.

[6] Zaichick VY, Sviridova TV, Zaichick SV. Zinc in the human prostate gland: normal, hyperplastic and cancerous. Int Urol Nephrol 1997; 29: 565-574.

[7] Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999; 40: 200-207.

[8] Untergasser G, Rumpold H, Plas E, Witkowski M, Pfister G, Berger P. High levels of zinc ions induce loss of mitochondrial potential and degradation of antiapoptotic Bcl-2 protein in in vitro cultivated human prostate epithelial cells. Biochem Biophys Res Commun 2000; 279: 607-614.

[9] Golovine K, Uzzo RG, Makhov P, Crispen PL, Kunkle D, Kolenko VM. Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-κB-dependent pathway. Prostate 2008; 68: 1443-1449.

[10] Banudevi S, Senthilkumar K, Sharmila G, Arunkumar R, Viiavababu MR, Arunakaran J. Effect of zinc on regulation of insulin-like growth factor signaling in human androgen-independent prostate cancer cells. Clin Chimica Acta 2010; 411: 172-178.

[11] Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2003; 95: 1004-007.

[12] Jonsson M, Lundwall Å, Malm J. The semenogelins: proteins with functions beyond reproduction? Cell Mol Life Sci 2006; 63: 2886-2888.

[13] Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987; 80: 281-285.

[14] Jonsson M, Linse S, Frohm B, Lundwall Å, Malm J. Semenogelins I and II bind zinc and regulate the activity of prostate-specific antigen. Biochem J 2005; 387: 447-453.

[15] Lundwall Å, Bjartell A, Olsson AY, Malm J. Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Hum Reprod 2002; 8: 805-810.

[16] Bonilha VL, Rayborn ME, Shadrach K, Lundwall Å, Malm J, Bhattacharya SK, Crabb JW, Hollyfield JG. Characterization of semenogelin proteins in the human retina. Exp Eye Res 2006; 83: 120-127.

[17] Canacci AM, Izumi K, Zheng Y, Gordetsky J, Yao JL, Miyamoto H. Expression of semenogelins I and II and its prognostic significance in human prostate cancer. Prostate 2011; 71: 1108-1114.

[18] Izumi K, Li Y, Zheng Y, Gordetsky J, Yao JL, Miyamoto H. Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy. Hum Pathol 2012; 43: 1991-2000.

[19] Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H. Androgen activates β-catenin signaling in bladder cancer cells. Endocr Relat Cancer 2013; 20: 293-304.

[20] Miyamoto H, Marwah P, Marwah A, Yang Z, Chung CY, Altuwaijri S, Chang C, Lardy H. Identification of steroid derivatives that function as potent antiandrogens. Int J Cancer 2005; 117: 866-872.

[21] Zheng Y, Izumi K, Li Y, Ishiguro H, Miyamoto H. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals. Mol Cancer Ther 2012; 11: 2621-2632.

[22] Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res 2014; 4: 461-473.

[23] Bao B, Prasad AS, Beck FWJ, Godmere M. Zinc modulates mRNA levels of cytokines. Am J Physiol Endocrinol Metab 2003; 285: E1095-E1102.

[24] Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003; 22: 6005-6012.

[25] Markov P, Golovine K, Uzzo RG. Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells. Gene 2009; 431: 38-48.

[26] Shiota M, Yokomizo A, Fujimoto N, Naito S. Androgen receptor cofactors in prostate cancer: Potential therapeutic targets of castration-resistant prostate cancer. Curr Cancer Drug Tar 2011; 11: 870-881.

[27] Kawahara T, Miyamoto H. Androgen receptor antagonists in the treatment of prostate cancer. Clin Immunol Endocr Metab Drugs 2014; 1: 11-19.

[28] Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC, Chang C. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 2008; 68: 7110-7119.

[29] Berti A, Virgili A, D'Errico G, Vespi G, Lago G, Cavazzana A. Expression of seminal vesicle-specific antigen in serum of lung tumor patients. J Forensic Sci 2005; 50: 1114-1115.

and severity of tumours in PTEN conditional knockout mice with prostate-specific deletion of PTEN, correlates with the estrogen sensitivity of each lobe of the prostate. Therefore, we hypothesized that this model could be used to study the role of ERα in prostate cancer progression.

METHODS: Immunohistochemistry and stereology were used to quantify ERα and Ki67 expression in PTEN null mice. To assess the functional role of ERα, a cell line derived from a PTEN null tumour was treated with shRNA or TPSF, a non-competitive ERα antagonist. Rescue experiments with expression constructs for either full length ERα, capable of genomic and non-genomic actions, or membrane-only ERα, only able to trigger rapid non-genomic signalling, were used to determine the mechanism underlying ERα-regulated proliferation.

RESULTS: There was a dramatic increase in ERα expression in prostate tumours of PTEN null mice compared with normal prostates of control animals. Within the PTEN null prostate, there was a consistent pattern of ERα expression: low in benign glands, moderate in tumours within the dorsal, lateral and ventral lobes, and high in tumours within the anterior prostate. This pattern significantly correlated with the levels of the proliferative marker Ki67. There was also a significant correlation between ERα and Ki67 within individual malignant glands in the anterior prostate. In vitro knockdown of ERα attenuated the proliferation of PTEN null cells as did treatment with TPSF. Loss of ERα reduced the activity of both the PI3K and MAPK pathways and decreased MYC levels. This effect was reversed by re-expressing full-length or membrane-only ERα.

CONCLUSIONS: Collectively, these results demonstrate that ERα drives the proliferation of prostate cancer cells through classical genomic and rapid non-genomic signalling.

MP31-08
SEMENOGELIN I PROMOTES PROSTATE CANCER CELL GROWTH VIA FUNCTIONING AS AN ANDROGEN RECEPTOR COACTIVATOR AND PROTECTING AGAINST ZINC CYTOTOXICITY

Hitoshi Ishiguro*, Baltimore, MD; Koji Izumi, Yi Li, Rochester, NY; Yichun Zheng, Eiji Kashiwagi, Takashi Kawahara, Hiroshi Miyamoto, Baltimore, MD

INTRODUCTION AND OBJECTIVES: A seminal plasma protein, semenogelin I (SgI), contributes to semen clotting, upon binding to Zn^{2+}, and can be proteolyzed by prostate-specific antigen (PSA) to release the encased spermatozoa after ejaculation. In contrast to the well-recognized physiological actions of semenogelins, their role in human malignancies remains poorly understood. We have demonstrated that SgI is overexpressed in prostate cancer tissues and its expression is enhanced by zinc treatment in LNCaP cells. In the current study, using cell lines stably expressing SgI, we investigated its biological functions in prostate cancer.

METHODS: We assessed the effects of SgI, in conjunction with zinc and androgen, on cell growth and androgen receptor (AR) in prostate cancer lines, using western blotting, MTT assay, transwell invasion assay, luciferase assay, and co-immunoprecipitaion assay.

RESULTS: Even though SgI is a secreted protein, immunoblots detected signals in conditioned medium only after culturing SgI-overexpressing cells, but not control LNCaP with endogenous SgI, suggesting that prostate cancer cells do not generally secrete a large amount of SgI. Zinc, without SgI, inhibited cell growth of both AR-positive and AR-negative lines. Co-expression of SgI induced dihydrotestosterone (DHT)-mediated proliferation of AR-positive cells when cultured with zinc, whereas SgI and/or DHT showed marginal effects in AR-negative cells. Similarly, SgI enhanced DHT-induced cell

invasion only in the presence of high-level zinc. Moreover, overexpression of SgI induced DHT-mediated PSA expression in cancer cells, whereas SgI showed marginal induction without DHT. In a reporter gene assay, SgI showed a slight inhibitory effect (15% decrease) at 0 μM zinc, a slight stimulatory effect (31% increase) at 15 μM zinc, or a significant stimulatory effect (3.2-fold) at 100 μM zinc on DHT-enhanced AR transactivation. Co-immunoprecipitation then demonstrated DHT-induced physical interactions between AR and SgI.

CONCLUSIONS: We show molecular evidence indicating that cellular SgI, as a new AR coactivator, enhances the transcriptional activity of the receptor in the presence of high levels of zinc and promotes androgen-mediated prostate cancer progression. Our results may also provide an underlying reason why prostate cancer tissue contains relatively high levels of zinc which by itself shows an inhibitory effect on tumor growth.

MP31-09
IDENTIFICATION OF A RETRO-TRANSPOSON DERIVED GENE ASSOCIATED WITH PROGRESSION TO NEUROENDOCRINE PROSTATE CANCER.

Shusuke Akamatsu*, Alexander Wyatt, Dong Lin, Summer Lysakowski, Fan Zhang, Soojin Kim, Ladan Fazli, Vancouver, Canada; Himisha Beltran, Mark Rubin, New York, NY; Amina Zoubeidi, Yuzhuo Wang, Colin Collins, Martin Gleave, Vancouver, Canada

INTRODUCTION AND OBJECTIVES: The treatment of castration resistant prostate cancer has dramatically improved with the recent development of potent androgen receptor (AR) pathway inhibitors. However, stronger AR pathway inhibition appears to be driving resistance mechanisms that are independent of the AR axis, the most recognized of which is neuroendocrine prostate cancer (NEPC). To date, few genes have been associated with progression to NEPC. We developed a patient-derived xenograft model of NEPC trans-differentiation: a hormone-naïve adenocarcinoma that upon AR-blockade initially regresses, but rapidly relapses as NEPC. In this study, we carried out longitudinal expression profiling of xenograft tumors during the trans-differentiation process to identify genes associated with tumor cell survival post-castration and the development NEPC.

METHODS: Gene profiling of xenografts collected at different time points during the trans-differentiation were compared to data sets of human NEPC. Immunohistochemistry was performed using clinical NEPC samples. Loss of function studies were carried out using siRNA and shRNA in cell growth (WST-8), invasion (Boyden chamber) and migration (scratch) assays.

RESULTS: We identified a retro-transposon derived gene, Paternally Expressed 10 (PEG10), to be highly expressed during the early trans-differentiation stage and also in clinical NEPC. We confirmed at the protein level that PEG10 is up-regulated post-castration and further significantly elevated in terminal NEPC. PEG10 was highly expressed within NEPC foci of clinical samples. Knockdown of PEG10 in prostate cancer (PC) cells induced apoptosis and G0/G1 arrest, and also attenuated invasion and migration. We found PEG10 knockdown inhibited invasion and migration induced by TGF-β, and modulated response of the cells to TGF-β, resulting in decreased phosphorylation of Smad2 and Smad3, decrease in SBE4 luciferase reporter activity, and inhibition of Snail and Zeb1 induction. Collectively, these data show that PEG10 promotes PC cell growth, and also co-operates with TGF-β to promote invasion and migration of PC cells, conferring aggressive phenotype to these cells.

CONCLUSIONS: PEG10 is a gene associated both with growth and invasion of NEPC, and is a potential novel therapeutic target for the treatment of NEPC.